Novo Nordisk (Novo Nordisk) announced the hypoglycemic drug Ozempic (Chinese trade name : Nuo Hetai®, generic name: semaglutide, semaglutide, subcutaneous preparation, once a week) in the treatment of type 2 diabetes (T2D) phase 3b SUSTAIN FORTE trial results. The data showed that compared with the approved 1.0mg dose of Ozempic, the 2.0mg dose of Ozempic under investigation showed statistically significant and superior blood glucose (HbA1C) lowering efficacy.